Showing results (21-30 of 95) with videos related to

Sort By:
Pageof 10
Glycoconjugate Journal|February 6, 2004
90K (Mac-2 BP) and galectins in tumor progression and metastasisAntonino Grassadonia, Nicola Tinari, Ida Iurisci, et al.
Oncotarget|February 27, 2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survivalNicola Tinari, Rossano Lattanzio, Clara Natoli, et al.
Oncotargets and Therapy|July 4, 2017
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impactsMichele De Tursi, Marinella Zilli, Consiglia Carella, et al.
Plos One|April 10, 2014
Breast cancer "tailored follow-up" in Italian oncology units: a web-based surveyClara Natoli, Davide Brocco, Isabella Sperduti, et al.
Thoracic Cancer|February 2, 2018
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practiceAlessio Cortellini, Elisabetta Gambale, Katia Cannita, et al.
Oncotarget|January 6, 2017
"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsLorena Incorvaia, Francesc Passiglia, Sergio Rizzo, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
International Journal of Cancer|October 24, 2008
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapiesNicola Tinari, Rossano Lattanzio, Patrizia Querzoli, et al.
Oncotarget|October 3, 2015
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentEnrico Bronte, Giuseppe Bronte, Giuseppina Novo, et al.
Pageof 10